Key result
Amrinone, enoximone, and milrinone produce positive chronotropic, inotropic, and lusitropic effects without direct coronary vasodilation.
Why the study?
Do amrinone, enoximone, and milrinone have dissimilar concentration-dependent effects on cardiac function and metabolism in isolated guinea pig hearts?
Do amrinone, enoximone, and milrinone have dissimilar concentration-dependent effects on cardiac function and metabolism in isolated guinea pig hearts?
Milrinone has the most prominent effects on contractility and relaxation at clinically relevant concentrations among the tested PDE3 inhibitors, which increase coronary flow secondary to metabolic demand rather than direct vasodilation.
Answers are grounded in this paper and cite their sources.
Should not guide PDE3 inhibitor use in patients; leaves open translation of metabolic coronary flow mechanisms to humans.
In Brief Little is known about of the comparative cardiac lusitropic and coronary vasoactive effects of type III phosphodiesterase inhibitors independent of their systemic circulatory effects. We hypothesized that phosphodiesterase inhibitors have dissimilar concentration-dependent effects on cardiac function and metabolism and that their coronary vasodilatory effects are solely dependent on flow autoregulation secondary to positive inotropic effects. Our aim was to compare the dose-response electrophysiologic, mechanical, vasodilatory, and metabolic properties of three clinically available phosphodiesterase inhibitors in isolated Langendorff perfused guinea pig hearts. We found that, over a range from 10−7 to 10−4 M, amrinone, enoximone, and milrinone each produced maximal concentration-dependent positive chronotropic (12%, 18%, 26%), inotropic (16%, 26%, 26%), and lusitropic (14%, 21%, 19%) effects. At clinical concentrations, all phosphodiesterase inhibitors increased heart rate, but only milrinone significantly enhanced contractility and relaxation (11%). Each phosphodiesterase inhibitor similarly increased contractility at its highest concentration; this was accompanied by an increase in oxygen consumption, which was matched by comparable increases in coronary flow and oxygen delivery. Coronary flow reserve was preserved at the highest concentration of each drug, indicating that an increased metabolic rate was responsible for the increase in coronary flow by each drug at each concentration. Over the concentrations examined, we conclude that each of the phosphodiesterase inhibitors does not directly promote coronary vasodilation and that milrinone has the most prominent effects on contractility and relaxation at clinically relevant concentrations. IMPLICATIONS: In the isolated Langendorff heart, amrinone, enoximone, and milrinone dose-dependently produced positive chronotropic, inotropic, and lusitropic effects, although only enoximone and milrinone increased oxygen consumption. Coronary flow reserve was preserved by each drug, indicating an intact coronary autoregulation. In addition, these tested phosphodiesterase inhibitors do not directly cause coronary vasodilation.
No takes yet. Share an insight, caveat, or question.
Zausig et al. (2006) studied Isolated Langendorff perfused guinea pig hearts. Phosphodiesterase type III inhibitors (amrinone, enoximone, milrinone) was evaluated on Electrophysiologic, mechanical, vasodilatory, and metabolic properties. In isolated guinea pig hearts, amrinone, enoximone, and milrinone produced dose-dependent positive chronotropic, inotropic, and lusitropic effects without directly causing coronary vasodilation.
Synapse has enriched 10 related papers. Consider them for comparative context: